SCHEDULE 13G/A: Frazier Life Sciences Funds Update Passive Stake in Savara Inc. to 6.6%

Frazier Life Sciences and affiliated entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 6.6% in Savara Inc. Common Stock as of March 31, 2025.

Summary

• Frazier Life Sciences Public Fund, L.P., along with its general partners FHMLSP, L.P. and FHMLSP, L.L.C., beneficially owns 6,745,296 shares of Savara Inc. Common Stock, representing 3.9% of the class.
• Frazier Life Sciences Public Overage Fund, L.P., and its related entities FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C., beneficially owns 2,889,469 shares, representing 1.7% of the class.
• Frazier Life Sciences X, L.P., and its related entities FHMLS X, L.P. and FHMLS X, L.L.C., beneficially owns 324,346 shares, representing 0.2% of the class.
• Frazier Life Sciences XI, L.P., and its related entities FHMLS XI, L.P. and FHMLS XI, L.L.C., beneficially owns 1,503,190 shares, representing 0.9% of the class.
• James N. Topper and Patrick J. Heron each share voting and dispositive power over an aggregate of 11,462,301 shares, which constitutes 6.6% of Savara Inc.'s Common Stock.
• Albert Cha and James Brush each share voting and dispositive power over an aggregate of 9,634,765 shares, representing 5.6% of the class.
• Daniel Estes shares voting and dispositive power over 1,503,190 shares, representing 0.9% of the class.
• The percentages are calculated based on 172,633,140 shares of Common Stock outstanding as of March 27, 2025, as reported in Savara Inc.'s Annual Report on Form 10-K.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of Savara Inc.

Sentiment

Score: 5

Explanation: This is a routine beneficial ownership disclosure and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It simply updates the public record of a significant, passive investment.

Risks

• The filing explicitly states that the shares are not held for the purpose of or with the effect of changing or influencing the control of the issuer, indicating a passive investment stance.

Future Outlook

This Schedule 13G/A filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Savara Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure by an institutional investor group, Frazier Life Sciences, updating their passive ownership stake in Savara Inc., a publicly traded company. Such filings provide transparency on significant shareholder positions but do not typically offer insights into broader industry trends or competitive dynamics beyond confirming continued investment interest in the biotechnology sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership structure of a significant institutional investor group in Savara Inc.

Key Dates

Keywords

Savara Inc., Frazier Life Sciences, Beneficial Ownership, Schedule 13G/A, SEC Filing, Institutional Investor, Common Stock, Passive Investment, Biotechnology